Display options
Cite
Cui H, Wang Q, Miller DD, et al. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma. Front Pharmacol. 2021;12:637098doi: 10.3389/fphar.2021.637098.
Cui, H., Wang, Q., Miller, D. D., & Li, W. (2021). The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma. Frontiers in pharmacology, 12637098. https://doi.org/10.3389/fphar.2021.637098
Cui, Hongmei, et al. "The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma." Frontiers in pharmacology vol. 12 (2021): 637098. doi: https://doi.org/10.3389/fphar.2021.637098
Cui H, Wang Q, Miller DD, Li W. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma. Front Pharmacol. 2021 Mar 25;12:637098. doi: 10.3389/fphar.2021.637098. eCollection 2021. PMID: 33841154; PMCID: PMC8027488.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2021 Mar 25;12:637098. doi: 10.3389/fphar.2021.637098. eCollection 2021.

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.

Frontiers in pharmacology

Hongmei Cui, Qinghui Wang, Duane D Miller, Wei Li

Affiliations

  1. Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, United States.
  2. Institute of Toxicology, School of Public Health, Lanzhou University, Lanzhou, China.

PMID: 33841154 PMCID: PMC8027488 DOI: 10.3389/fphar.2021.637098

Abstract

Melanoma is one of the deadliest skin cancers having a five-year survival rate around 15-20%. An overactivated MAPK/AKT pathway is well-established in BRAF mutant melanoma. Vemurafenib (Vem) was the first FDA-approved BRAF inhibitor and gained great clinical success in treating late-stage melanoma. However, most patients develop acquired resistance to Vem within 6-9 months. Therefore, developing a new treatment strategy to overcome Vem-resistance is highly significant. Our previous study reported that the combination of a tubulin inhibitor ABI-274 with Vem showed a significant synergistic effect to sensitize Vem-resistant melanoma both

Copyright © 2021 Cui, Wang, Miller and Li.

Keywords: ERK; VERU-111; akt; melanoma; skp2; vemurafenib-resistance

Conflict of interest statement

WL is a scientific consultant for Veru, Inc. who licensed VERU-111 for commercial development. WL and DM also report receiving sponsored research agreement grants from Veru, Inc. The remaining authors

References

  1. Expert Rev Clin Pharmacol. 2019 Mar;12(3):259-266 - PubMed
  2. Br J Cancer. 2014 Apr 15;110(8):1958-67 - PubMed
  3. Biochem Pharmacol. 2018 Dec;158:84-94 - PubMed
  4. Oncol Rep. 2016 Jul;36(1):559-66 - PubMed
  5. J Med Chem. 2010 Oct 28;53(20):7414-27 - PubMed
  6. N Engl J Med. 2015 Jan 1;372(1):30-9 - PubMed
  7. Clin Cancer Res. 2014 May 15;20(10):2516-22 - PubMed
  8. Bioorg Med Chem. 2011 Oct 15;19(20):6006-14 - PubMed
  9. J Exp Clin Cancer Res. 2019 Jan 23;38(1):29 - PubMed
  10. Curr Med Chem. 2020;27(39):6573-6595 - PubMed
  11. Cancers (Basel). 2020 Feb 19;12(2): - PubMed
  12. Cell Cycle. 2015;14(24):3877-84 - PubMed
  13. J Med Chem. 2020 Jan 23;63(2):827-846 - PubMed
  14. BioDrugs. 2017 Feb;31(1):51-61 - PubMed
  15. Oncogene. 2003 Dec 8;22(56):9075-86 - PubMed
  16. Oncotarget. 2017 Jul 18;8(29):47490-47496 - PubMed
  17. Nature. 2014 Sep 4;513(7516):105-9 - PubMed
  18. Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):317-330 - PubMed
  19. Eur J Cancer. 2016 Mar;55:98-110 - PubMed
  20. Mol Med Rep. 2017 Jan;15(1):317-322 - PubMed
  21. Blood. 2011 Nov 17;118(20):5429-38 - PubMed
  22. J Med Chem. 2012 Aug 23;55(16):7285-9 - PubMed
  23. Mol Cancer Ther. 2020 Feb;19(2):348-363 - PubMed
  24. Mol Cancer Ther. 2014 Jan;13(1):16-26 - PubMed
  25. J Med Chem. 2014 Sep 11;57(17):7355-66 - PubMed
  26. J Med Chem. 2018 Sep 13;61(17):7877-7891 - PubMed
  27. Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9629-9634 - PubMed
  28. J Med Chem. 2019 Jul 25;62(14):6734-6750 - PubMed
  29. Cancers (Basel). 2018 May 24;10(6): - PubMed
  30. Int J Oncol. 2007 Aug;31(2):277-83 - PubMed
  31. Med Oncol. 2013 Dec;30(4):735 - PubMed
  32. Drugs. 2018 Aug;78(12):1277-1284 - PubMed
  33. PLoS Comput Biol. 2020 Dec 28;16(12):e1008538 - PubMed
  34. J Biol Chem. 2015 Jan 30;290(5):2879-87 - PubMed
  35. Onco Targets Ther. 2013 Nov 28;6:1649-58 - PubMed
  36. Expert Opin Pharmacother. 2016;17(7):1031-8 - PubMed
  37. Cancer Lett. 2020 Dec 28;495:76-88 - PubMed
  38. Cancer Res. 2018 Jan 1;78(1):265-277 - PubMed
  39. Cancer. 2017 Jun 1;123(S11):2118-2129 - PubMed
  40. Int J Cancer. 2006 Jan 15;118(2):472-6 - PubMed
  41. Oncotarget. 2018 Jul 13;9(54):30450-30464 - PubMed
  42. Oncotarget. 2018 Nov 23;9(92):36503-36514 - PubMed
  43. Am J Cancer Res. 2018 Sep 01;8(9):1812-1822 - PubMed
  44. Melanoma Res. 2018 Dec;28(6):521-526 - PubMed
  45. Sci Signal. 2018 Mar 13;11(521): - PubMed
  46. J Clin Oncol. 2018 Dec 10;36(35):3441-3449 - PubMed
  47. Mol Biol Cell. 2008 Nov;19(11):4602-10 - PubMed
  48. Dev Cell. 2004 May;6(5):661-72 - PubMed
  49. Cell. 2012 Nov 9;151(4):913-914 - PubMed
  50. Int J Oncol. 2011 Jan;38(1):219-25 - PubMed
  51. Cancer Res. 2012 Feb 15;72(4):969-78 - PubMed
  52. Cancer Cell Int. 2014 Nov 30;14(1):126 - PubMed
  53. Onco Targets Ther. 2017 Jan 18;10:439-446 - PubMed
  54. Ann Oncol. 2017 Jul 1;28(7):1631-1639 - PubMed
  55. Cancer Res. 2018 Feb 15;78(4):1017-1030 - PubMed
  56. Biochem Pharmacol. 2012 Jan 1;83(1):16-26 - PubMed
  57. Oncotarget. 2017 May 9;8(42):71782-71796 - PubMed
  58. PLoS One. 2009;4(3):e4881 - PubMed
  59. Cancer Lett. 2020 Feb 1;470:64-74 - PubMed
  60. Cancer Res. 2006 Apr 15;66(8):4020-9 - PubMed
  61. Oncol Lett. 2018 Jun;15(6):8891-8900 - PubMed
  62. Biochem Biophys Res Commun. 2020 Mar 26;524(1):28-35 - PubMed
  63. PLoS One. 2011;6(12):e28973 - PubMed

Publication Types

Grant support